Expression, purification and activity determination of humanized anti-HER2 monoelonal antibody in CHO

Chinese Pharmaceutical Journal

Volumn 47, Issue 11, 2012, Pages 884-888

  Huang, Li ^a   Li, Mei Xiang ^a   Lei, Yun ^a   Wang, Yi Ting ^a   Xie, Kui ^a   Yang, Yi Li ^a   Chen, Bao Qiong ^a   Xie, Qiu Ling ^a   Hong, An ^a   Xiong, Sheng ^a  

^a GUANGZHOU UNIVERSITY   (China)

Author keywords

Analysis bioactivity; Breast cancer; CHO cells; Humanized anti HER2 monoclonal antibody; Magnifying culture; Orbital shake bioreactor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; RECOMBINANT HUMANIZED HER2 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; BIOREACTOR; CELL CLONE; CHO CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

EID: 84866449954     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. JEMAL A, SIEGEL R, XU J, et al. Cancer statistics, 2010 [J]. Wiley Online Library, 2010, 60(5):277-300.
2. PEROU C M, SØRLIE T, EISEN M B, et al. Molecular portraits of human breast tumours [J]. Nature Publishing Group, 2000, 406(6):747-752.
3. PRAT A, PEROU C M. Deconstructing the molecular portraits of breast cancer [J]. Molecular Oncology, 2011, 5(1):5-23.
4. KANG Y H, FAN M. Humanized anti-HER2 monoclonal antibody pertuzumab [J]. Prog Pharm Sci, 2009, 33(4):182-184.
5. NEYT M, ALBRECHT J, COCQUYT V. An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial[J]. Ann Oncol, 2006, 17(3): 381-390.
6. BUTLER M. Animal cell cultures; recent achievements and perspectives in the production of biopharmaceuticals [J]. Appl Microbiol Biotechnol, 2005, 68(3):283-291.
7. GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011, 22(8):1736-1747.
8. ZHANG X, STETTLER M, REIF O, et al. Shaken helical track bioreactors; providing oxygen to high-density cultures of mammalian cells at volumes up to 1000 L by surface aeration with air [J]. Elsevier, 2008, 25(1):68-75.
9. DOVE A. Betting on biogenerics[J]. Nature Biotechnol, 2001, 19(2):117-120.
10. CHEN C. Challenges and opportunities of monoclonal antibody manufacturing in China[J]. Medical Reviews, 2009, 5(3):28-33.
11. AGGARWAL S. Corrigendum: What's fueling the biotech engine-2007 [J]. Nature Publishing Group, 2009, 27(2): 205.